Core Insights - ALX Oncology announced that results from a Phase 1b/2 trial of evorpacept in combination with zanidatamab for HER2-positive and HER2-low metastatic breast cancer will be presented at the San Antonio Breast Cancer Symposium in December 2024 [1][2] Group 1: Clinical Trial Details - The Phase 1b/2 clinical trial is an open-label, multicenter study (NCT05027139) assessing evorpacept and zanidatamab as a treatment for HER2-expressing breast cancer and other cancers [2] - The presentation will include the title "Zanidatamab in combination with evorpacept in HER2-positive and HER2-low metastatic breast cancer: Results from a phase 1b/2 study" with Abstract Number SESS-2007 [2] - The presentation is scheduled for December 12, 2024, from 7:00 a.m. to 8:30 a.m. CST at the Henry B. Gonzalez Convention Center, San Antonio, Texas [2] Group 2: Company Overview - ALX Oncology is a clinical-stage biotechnology company focused on developing therapies that enhance the immune system to treat cancer and improve patient survival [3] - The lead therapeutic candidate, evorpacept, is positioned as a potential cornerstone therapy for future immuno-oncology treatments and is being evaluated in multiple ongoing clinical trials across various cancer indications [3]
ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024